Temporal characteristics of botulinum neurotoxin therapy

Expert Review of Neurotherapeutics

Volumn 10, Issue 1, 2010, Pages 93-103

  Lebeda, Frank J ^a   Cer, Regina Z ^b   Stephens, Robert M ^b   Mudunuri, Uma ^b  

^a U S ARMY MEDICAL RESEARCH AND MATERIEL COMMAND   (United States)

^b SAIC FREDERICK INC   (United States)

Author keywords

Antigenicity; Decay; Diffusion; Duration; Immunogenicity; Onset; Persistence; Spread; Waning

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B;

BLEPHAROSPASM; CERVICAL DYSTONIA; CLINICAL TRIAL; COMPUTER AIDED DESIGN; DOSE RESPONSE; DRUG EFFICACY; DYSTONIA; HEMIFACIAL SPASM; HUMAN; LATENT PERIOD; MATHEMATICAL MODEL; MEDICAL DECISION MAKING; NERVE STIMULATION; NEUROLOGIC DISEASE; NEUROMUSCULAR SYNAPSE; REVIEW; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT; XEROSTOMIA;

ACTION POTENTIALS; ANIMALS; ANTI-DYSKINESIA AGENTS; BOTULINUM TOXINS; COMPUTATIONAL BIOLOGY; HUMANS; MODELS, NEUROLOGICAL; MODELS, THEORETICAL; MUSCLE, SKELETAL; NERVOUS SYSTEM DISEASES; SYNAPTOSOMAL-ASSOCIATED PROTEIN 25; TIME FACTORS;

EID: 74949144185     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.09.134     Document Type: Review

References (79)

1. Adam OR, Jankovic J. Treatment of dystonia. Parkinsonism Relat. Disord. 13(Suppl. 3), S362-S368 (2007).
2. Simpson LL. Identification of the major steps in botulinum toxin action. Annu. Rev. Pharmacol. Toxicol. 44, 167-193 (2004).
3. Schiavo G, Matteoli M, Montecucco C. Neurotoxins affecting neuroexocytosis. Physiol. Rev. 80, 717-766 (2000).
4. Morbiato L, Carli L, Johnson EA, Montecucco C, Molgo J, Rossetto O. Neuromuscular paralysis and recovery in mice injected with botulinum neurotoxins A and C. Eur. J. Neurosci. 25, 2697-2704 (2007).
5. Lawrence G, Wang J, Chion CK, Aoki KR, Dolly JO. Two protein trafficking processes at motor nerve endings unveiled by botulinum neurotoxin E. J. Pharmacol. Exp. Ther. 320, 410-418 (2007).
6. Lebeda FJ, Adler M, Erickson K, Chushak Y. Onset dynamics of type A botulinum neurotoxin-induced paralysis. J. Pharmacokinet. Pharmacodyn. 35, 251-267 (2008). • Detailed kinetic treatment and extension of Simpson's minimal kinetic model for botulinum neurotoxin A.
7. Simpson LL. Kinetic studies on the interaction between botulinum toxin type A and the cholinergic neuromuscular junction. J. Pharmacol. Exp. Ther. 212, 16-21 (1980). •• Describes the original experimental observations that served as the foundation of the minimal model for botulinum neurotoxin A and the onset of paralysis at the neuromuscular junction.
8. Sampaio C, Costa J, Ferreira JJ. Clinical comparability of marketed formulations of botulinum toxin. Mov. Disord. 19(Suppl. 8), S129-S136 (2004).
9. Naumann M, So Y, Argoff CE et al. Assessment: botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 70, 1707-1714 (2008).
10. Simpson DM, Blitzer A, Brashear A et al. Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 70, 1699-1706 (2008).
11. Simpson DM, Gracies JM, Graham HK et al. Assessment: botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 70, 1691-1698 (2008).
12. Mudunuri U, Stephens R, Bruining D, Liu D, Lebeda FJ. BotXminer: mining biomedical literature with a new web-based application. Nucleic Acids Res. 34, W748-W752 (2006).
13. Hines HB, Lebeda F, Hale M, Brueggemann EE. Characterization of botulinum progenitor toxins by mass spectrometry. Appl. Environ. Microbiol. 71, 4478-4486 (2005).
14. Barr JR, Moura H, Boyer AE et al. Botulinum neurotoxin detection and differentiation by mass spectrometry. Emerg. Infect. Dis. 11, 1578-1583 (2005).
15. Figgitt DP, Noble S. Botulinum toxin B: a review of its therapeutic potential in the management of cervical dystonia. Drugs 62, 705-722 (2002).
16. Molho E, Jankovic J, Lew M. Role of botulinum toxin in the treatment of cervical dystonia. Neurol. Clin. 26(Suppl. 1), 43-53 (2008).
17. Dressler D, Hallett M. Immunological aspects of Botox, Dysport and Myobloc/NeuroBloc. Eur. J. Neurol. 13(Suppl. 1), 11-15 (2006).
18. Carruthers A, Carruthers J. Botulinum toxin products overview. Skin Therapy Lett. 13, 1-4 (2008).
19. Hunt T, Clarke K. Potency of the botulinum toxin product CNBTX-A significantly exceeds labeled units in standard potency test. J. Am. Acad. Dermatol. 58, 517-518 (2008).
20. Taban M, Perry JD. Pearls of botox usage. Oculoplastic Surgery 4, 165-169 (2006).
21. Brin MF, Blitzer A. Botulinum toxin: dangerous terminology errors. J. R. Soc. Med. 86, 493-494 (1993).
22. Niemann H. Clostridial neurotoxins - proposal of a common nomenclature. Toxicon 30, 223-225 (1992).
23. Lebeda FJ. BotDB: a database resource for the clostridial neurotoxins. Mov. Disord. 19(Suppl. 8), S35-S41 (2004).
24. Cer RZ, Mudunuri U, Stephens R, Lebeda FJ. IC50-to-Ki: a web-based tool for converting IC50 to Ki values for inhibitors of enzyme activity and ligand binding. Nucleic Acids Res. 37, W441-W445 (2009).
25. Lim EC, Seet RC. Botulinum toxin: description of injection techniques and examination of controversies surrounding toxin diffusion. Acta Neurol. Scand. 117, 73-84 (2008).
26. Jost WH, Kohl A, Brinkmann S, Comes G. Efficacy and tolerability of a botulinum toxin type A free of complexing proteins (NT 201) compared with commercially available botulinum toxin type A (BOTOX) in healthy volunteers. J. Neural Transm. 112, 905-913 (2005). •• Important research contribution that highlights the interpersonal variability of compound muscle action potential responses following toxin administration.
27. Kranz G, Haubenberger D, Voller B et al. Respective potencies of Botox and Dysport in a human skin model: a randomized, double-blind study. Mov. Disord. 24, 231-236 (2009).
28. Arndt JW, Gu J, Jaroszewski L et al. The structure of the neurotoxin-associated protein HA33/A from Clostridium botulinum suggests a reoccurring b-trefoil fold in the progenitor toxin complex. J. Mol. Biol. 346, 1083-1093 (2005).
29. Sheffield JK, Jankovic J. Botulinum toxin in the treatment of tremors, dystonias, sialorrhea and other symptoms associated with Parkinson's disease. Expert Rev. Neurother. 7(6), 637-647 (2007).
30. Moy R, Maas C, Monheit G, Huber MB. Long-term safety and efficacy of a new botulinum toxin type A in treating glabellar lines. Arch. Facial Plast. Surg. 11, 77-83 (2009).
31. Mejia NI, Vuong KD, Jankovic J. Long-term botulinum toxin efficacy, safety, and immunogenicity. Mov. Disord. 20, 592-597 (2005).
32. Mohammadi B, Kollewe K, Wegener M, Bigalke H, Dengler R. Experience with long-term treatment with albumin-supplemented botulinum toxin type A. J. Neural. Transm. 116, 437-441 (2009).
33. Jankovic J, Schwartz K, Clemence W, Aswad A, Mordaunt J. A randomized, double-blind, placebo-controlled study to evaluate botulinum toxin type A in essential hand tremor. Mov. Disord. 11, 250-256 (1996).
34. Matarasso SL. Comparison of botulinum toxin types A and B: a bilateral and double-blind randomized evaluation in the treatment of canthal rhytides. Dermatol. Surg. 29, 7-13 (2003).
35. Sadick NS, Faacs. Botulinum toxin type B for glabellar wrinkles: a prospective open-label response study. Dermatol. Surg. 28, 817-821 (2002).
36. Comella CL, Jankovic J, Shannon KM et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology 65, 1423-1429 (2005).
37. Aoki KR. Botulinum neurotoxin serotypes A and B preparations have different safety margins in preclinical models of muscle weakening efficacy and systemic safety. Toxicon 40, 923-928 (2002).
38. Dong M, Yeh F, Tepp WH et al. SV2 is the protein receptor for botulinum neurotoxin A. Science 312, 592-596 (2006).
39. Chen R, Karp BI, Goldstein SR, Bara-Jimenez W, Yaseen Z, Hallett M. Effect of muscle activity immediately after botulinum toxin injection for writer's cramp. Mov. Disord. 14, 307-312 (1999).
40. Dressler D, Adib Saberi F. Botulinum toxin: mechanisms of action. Eur. Neurol. 53, 3-9 (2005). •• Detailed study of the full time course and the development of resistance of the therapeutic effect of botulinum toxin with repeated applications.
41. Chancellor MB. Ten years single surgeon experience with botulinum toxin in the urinary tract; clinical observations and research discovery. Int. Urol. Nephrol. DOI: 10.1007/s11255-009-9600-7 (2009) (Epub ahead of print).
42. Eleopra R, Tugnoli V, Rossetto O, Montecucco C, De Grandis D. Botulinum neurotoxin serotype C: a novel effective botulinum toxin therapy in human. Neurosci. Lett. 224, 91-94 (1997).
43. Dolly JO, Aoki KR. The structure and mode of action of different botulinum toxins. Eur. J. Neurol. 13(Suppl. 4), 1-9 (2006). • Excellent review that contains valuable insights upon the persistance of type A neurotoxin.
44. Washbourne P, Pellizzari R, Rossetto O et al. On the action of botulinum neurotoxins A and E at cholinergic terminals. J. Physiol. Paris 92, 135-139 (1998).
45. Greene PE, Fahn S. Use of botulinum toxin type F injections to treat torticollis in patients with immunity to botulinum toxin type A. Mov. Disord 8, 479-483 (1993).
46. Matarasso A, Matarasso SL. Botulinum A exotoxin for the management of platysma bands. Plast. Reconstr. Surg. 112, 138S-140S (2003).
47. Sadick NS, Matarasso SL. Comparison of botulinum toxins A and B in the treatment of facial rhytides. Dermatol. Clin. 22, 221-226 (2004). • Important review that provides a comparison of kinetic features of botulinum toxins A and B.
48. Guyer BM. Some unresolved issues with botulinum toxin. J. Neurol. 248(Suppl. 1), 11-13 (2001).
49. Dressler D. Botulinum Toxin Therapy. Georg Thieme Verlag, Stuttgart, Germany (2000).
50. Brin MF, Comella CL, Jankovic J, Lai F, Naumann M. Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov. Disord. 23, 1353-1360 (2008).
51. Jankovic J, Hunter C, Dolimbek BZ et al. Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia. Neurology 67, 2233-2235 (2006).
52. Eleopra R, Tugnoli V, Quatrale R, Rossetto O, Montecucco C. Different types of botulinum toxin in humans. Mov. Disord 19(Suppl. 8), S53-S59 (2004).
53. Dressler D, Bigalke H. Botulinum toxin type B de novo therapy of cervical dystonia: frequency of antibody induced therapy failure. J. Neurol. 252, 904-907 (2005).
54. Dressler D. Clinical features of antibody-induced complete secondary failure of botulinum toxin therapy. Eur. Neurol. 48, 26-29 (2002). •• Contains details on the timing of the development of resitance (complete secondary therapeutic failure) to type B toxin.
55. de Sa Earp AP, Marmur ES. The five D's of botulinum toxin: doses, dilution, diffusion, duration and dogma. J. Cosmet. Laser Ther. 10, 93-102 (2008).
56. Laurent GJ, Millward DJ. Protein turnover during skeletal muscle hypertrophy. Fed. Proc. 39, 42-47 (1980).
57. Pearson CM. Histopathological features of muscle in the preclinical stages of muscular dystrophy. Brain 85, 109-120 (1962).
58. Lebeda FJ, Albuquerque EX. Membrane cable properties of normal and dystrophic chicken muscle fibers. Exp. Neurol. 47, 544-557 (1975).
59. Brin MF. Basic and clinical aspects of BOTOX. Toxicon 54, 676-682 (2009).
60. de Paiva A, Meunier FA, Molgo J, Aoki KR, Dolly JO. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc. Natl Acad. Sci. USA 96, 3200-3205 (1999).
61. Rogozhin AA, Pang KK, Bukharaeva E, Young C, Slater CR. Recovery of mouse neuromuscular junctions from single and repeated injections of botulinum neurotoxin A. J. Physiol. 586, 3163-3182 (2008).
62. Tintner R, Jankovic J. Botulinum toxin for the treatment of cervical dystonia. Expert Opin. Pharmacother. 2, 1985-1994 (2001).
63. Dolly JO, Williams RS, Black JD, Tse CK, Hambleton P, Melling J. Localization of sites for 125I-labelled botulinum neurotoxin at murine neuromuscular junction and its binding to rat brain synaptosomes. Toxicon 20, 141-148 (1982).
64. Amirali A, Sanders I. The glycogen depletion assay and the measurement of botulinum toxin injections In: Scientific and Therapeutic Aspects of Botulinum Toxin. Brin, M, Jankovic, J, Hallett, M (Eds). Lippincott Williams & Wilkins, PA, USA 135-141 (2002).
65. Jurasinski CV, Lieth E, Dang Do AN, Schengrund CL. Correlation of cleavage of SNAP-25 with muscle function in a rat model of botulinum neurotoxin type A induced paralysis. Toxicon 39, 1309-1315 (2001).
66. Kalandakanond S, Coffield JA. Cleavage of SNAP-25 by botulinum toxin type A requires receptor-mediated endocytosis, pH-dependent translocation, and zinc. J. Pharmacol. Exp. Ther. 296, 980-986 (2001).
67. Meunier FA, Lisk G, Sesardic D, Dolly JO. Dynamics of motor nerve terminal remodeling unveiled using SNARE-cleaving botulinum toxins: the extent and duration are dictated by the sites of SNAP-25 truncation. Mol. Cell. Neurosci. 22, 454-466 (2003).
68. Chushak Y, Foy BD, Frazier JM. Biomolecular Network Simulator. Software for stochastic simulation of cellular biological processes. In: Proceedings of the High Performance Computing Symposium (HPC 2007) Society for Modeling and Simulation International, VA, USA 345-349 (2007).
69. Chushak Y, Foy B, Fazier J. Stochastic simulations of cellular and biological processes. In: Proceedings of the Users Group Conference. Department of Defense High Performance Computing Modernization Program (DoD HPCMP), PA, USA 425-429 (2007).
70. Ditlevsen S, de Gaetano A. Stochastic vs. deterministic uptake of dodecanedioic acid by isolated rat livers. Bull. Math. Biol. 67, 547-561 (2005).
71. Gabler NB, Duan N, Liao D, Elmore JG, Ganiats TG, Kravitz RL. Dealing with heterogeneity of treatment effects: is the literature up to the challenge? Trials 10, 43 (2009).
72. McConnell P, Dash RC, Chilukuri R et al. The cancer translational research informatics platform. BMC Med. Inform. Decis. Mak. 8, 60 (2008).
73. Gentleman RC, Carey VJ, Bates DM et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 5, R80 (2004).
74. Lowe NJ, Yamauchi PS, Lask GP, Patnaik R, Moore D. Botulinum toxins types A and B for brow furrows: preliminary experiences with type B toxin dosing. J. Cosmet. Laser Ther. 4, 15-18 (2002).
75. Sadick NS. Prospective open-label study of botulinum toxin type B (MyoBloc) at doses of 2,400 and 3,000 U for the treatment of glabellar wrinkles. Dermatol. Surg. 29, 501-507 (2003).
76. Martin B. Botulinum toxin: the name game http://bmartinmd.com/2009/08/ botulinum-toxin-the-name-game.html (Accessed October 2009)
77. BotDB database http://botdb.abcc.ncifcrf.gov
78. Anonymous. FDA gives update on botulinum toxin safety warnings; established names of drugs changed www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm175013.htm (Accessed October 2009)
79. Allergan. Botox® cosmetic (onabotulinumtoxinA) for injection www.allergan.com/assets/pdf/botox-cosmetic-pi.pdf (2009) (Accessed October 2009)